MAY 31, 2024 by Children’s Hospital Los Angeles Credit: Molecular Cancer Research (2024). DOI: 10.1158/1541-7786.MCR-23-0741 Little is known about the genetics and biology of chordoma, a rare and aggressive bone tumor. Chordomas occur in approximately one in a million people in the U.S. a year and 5% of these are in children. These tumors can...
IMAGE: DR ELIZABETH ROUNDHILL, UNIVERSITY OF LEEDS CREDIT: UNVIERSITY OF LEEDS New research has revealed a way to help identify which patients with an aggressive type of bone cancer are least likely to be cured by current standard treatment. For around one in three patients diagnosed with Ewing sarcoma in just one part of the body –...
FEBRUARY 1ST, 2021POSTED BY JIM GOODWIN-WUSTL “In the future, we would like to add more metabolic therapies so that one day we might be able to eliminate the remaining chemotherapy drugs that these patients will still receive,” says Brian Van Tine. “The ultimate goal is to transform therapy by going after the metabolic properties that...
Researchers have used nanotechnology to identify a potentially groundbreaking treatment for an aggressive bone cancer that has proven disappointingly unresponsive to existing therapies, a new study shows. The new approach to treating chondrosarcoma, a rare cancer that typically afflicts adults and has poor survival rates, appears in the journal Molecular Cancer Therapeutics. The research, using...
A subset of bone cancer patients may respond to IGF1R inhibitors based on their genetic profile A subgroup of patients with osteosarcoma — a form of bone cancer — could be helped by an existing drug, suggest scientists from the Wellcome Trust Sanger Institute and their collaborators at University College London Cancer Institute and the...
